Positron Emission Tomography: Current Role for Diagnosis and Therapy Monitoring in Oncology.
Positron Emission Tomography: Current Role for Diagnosis and Therapy Monitoring in Oncology.
复制标题
正电子发射断层扫描：肿瘤学诊断和治疗监测的当前作用。
DOI：
--
复制
发表时间：
1997
期刊：
影响因子：
--
通讯作者：
L. Strauss
中科院分区：
文献类型：
--
作者：
L. Strauss
高分辨率横断面成像极大地改善了肿瘤患者的诊断和治疗管理，尽管有几个问题仍然悬而未决，主要涉及确切的初始分期、复发性肿瘤的鉴别诊断和治疗管理。正电子发射断层扫描（PET）是核医学领域的一种定量功能成像方式，有可能产生生理信息。 PET 肿瘤的诊断基于局部葡萄糖代谢的增加。此外，PET 可以作为监测治疗效果的宝贵工具。用于肿瘤学研究的最常见示踪剂是 F-18-脱氧葡萄糖 (FDG)，一种葡萄糖类似物。 FDG-PET 已在结直肠癌、恶性淋巴瘤、黑色素瘤、软组织肉瘤和肺部肿瘤等不同肿瘤类型中进行了评估，用于诊断原发性肿瘤和复发性病变。 PET-FDG 研究的敏感性超过 85%，具体取决于肿瘤类型、大小和位置。化疗后诊断存活的肿瘤组织是 PET 的另一个应用。 FDG-PET 研究的一个局限性是由于炎症等原因导致的假阳性结果。这个问题可以通过使用多示踪剂研究和/或标记的氨基酸来克服。可以使用不同的程序来评估治疗效果。 FDG 随访研究用于评估早期效果并预测长期反应。 F-18-氟尿嘧啶或 C-11-乙醇等标记治疗剂的药代动力学研究提供了有关药物转运和消除的专门定量数据。带有标记的细胞抑制药物的 PET 可以在化疗开始前进行预后。建议将此手术用于单一化疗。在接受联合化疗的患者中，需要评估不同的耐药机制，并且正在开发或已经用于科学目的的使用合适底物（例如 P-糖蛋白）的新方法。
High-resolution cross-sectional imaging improved dramatically the diagnosis and therapy management of oncological patients, although several questions remained open, primarily concerning the exact initial staging, the differential diagnosis of recurrent tumors, and therapy management. Positron emission tomography (PET) is a quantitative, functional imaging modality from the field of nuclear medicine which has the potential to yield physiological information. The diagnosis of tumors with PET is based on the increased regional glucose metabolism. Furthermore, PET can serve as a valuable tool for monitoring therapeutic effects. The most common tracer used for oncological studies is F-18-deoxyglucose (FDG), a glucose analog. FDG-PET has been evaluated in different tumor types such as colorectal cancer, malignant lymphomas, melanomas, soft-tissue sarcomas, and lung tumors for both the diagnosis of primary tumors and recurrent lesions. The sensitivity of PET-FDG studies exceeds 85%, dependent on tumor type, size, and location. The diagnosis of viable tumor tissue following chemotherapy is another application of PET. A limitation of FDG-PET studies is false positive results, e.g., due to inflammation. This problem may be overcome by the use of multitracer studies and/or labeled amino acids. Different procedures can be used to evaluate therapeutic effects. FDG follow-up studies are used to assess early effects and to predict long-term response. Pharmacokinetic studies of labeled therapeutic agents such as F-18-fluorouracil or C-11-ethanol provide exclusively quantitative data about transport and elimination of a drug. PET with labeled cytostatic drugs permits a prognosis prior to onset of chemotherapy. This procedure is recommended for monochemotherapy. In patients receiving polychemotherapy, the evaluation of different resistance mechanisms is needed and new approaches using suitable substrates, e.g., for the P-glycoprotein, are being developed or are already in use for scientific purposes.
登录
查看更多内容
影响因子：
19.7
作者：
WAHL, RL;QUINT, LE;ORRINGER, MB
通讯作者：
ORRINGER, MB
影响因子：
45.3
作者：
WAHL, RL;ZASADNY, K;CODY, R
通讯作者：
CODY, R
DOI：
--
发表时间：
1991-04
期刊：
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
影响因子：
--
作者：
L. Strauss;P. Conti
通讯作者：
L. Strauss;P. Conti
使用 2-氟-18-氟-2-脱氧-D-葡萄糖进行正电子发射断层扫描在恶性黑色素瘤成像中的初步评估。
DOI：
--
发表时间：
1993
期刊：
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
影响因子：
--
作者：
Gritters,LS;Francis,IR;Zasadny,KR;Wahl,RL
通讯作者：
Wahl,RL
[13N]顺铂 PET 用于评估恶性脑肿瘤的动脉内化疗与静脉化疗的药代动力学。
DOI：
--
发表时间：
1987
期刊：
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
影响因子：
--
作者：
Ginos,JZ;Cooper,AJ;Dhawan,V;Lai,JC;Strother,SC;Alcock,N;Rottenberg,DA
通讯作者：
Rottenberg,DA